# Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

> **NCT04934774** · PHASE1 · UNKNOWN · sponsor: **iCell Gene Therapeutics** · enrollment: 20 (estimated)

## Conditions studied

- T-cell Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Lymphoma
- T-cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** CD7 CAR T cells

## Key facts

- **NCT ID:** NCT04934774
- **Lead sponsor:** iCell Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-06-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04934774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04934774, "Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04934774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*